PSG1 recombinant protein containing FLAG and His tags and application thereof

By injecting the PSG1 recombinant protein containing FLAG and His tags in the early stage of embryonic development, the problem of the inability to directly treat congenital heart disease in the embryonic period is solved in the prior art, and the effect of improving placenta and heart development is achieved, providing safer More effective treatment options reduce the burden on patients and their families.

CN119080951APending Publication Date: 2024-12-06NANJING UNIV
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202411369764.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art lacks drugs that can directly treat congenital heart disease during the embryonic period, and surgical treatment has high risks and financial burdens, and cannot effectively correct fetal heart development abnormalities.

Method used

A PSG1 recombinant protein containing FLAG and His tags was developed, which was injected in the early stage of embryonic development through maternal intravenous administration, promotes the normal development of the placenta and the heart, improves the abnormal development of the placenta labyrinth and junction areas, and improves the heart structure.

Benefits of technology

Significantly improving embryonic heart structure and increasing the development of the ventricular wall, providing an earlier, safer and more effective potential strategy for the treatment of congenital heart disease, reducing the financial and psychological burden of patients and their families.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080951A_ABST
    Figure CN119080951A_ABST
Patent Text Reader

Abstract

The invention discloses a PSG1 recombinant protein containing FLAG and His tags and application of the PSG1 recombinant protein. The recombinant protein is constructed by adding FLAG and His tag sequences to the C tail end of a PSG1 gene sequence. The nucleotide sequence of the PSG1 recombinant protein containing FLAG and His tags is as shown in SEQ ID NO. 1. The invention relates to an application of a pregnancy specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags in preparation of drugs for placenta dysplasia and fetal birth defects. According to the invention, pregnancy-specific glycoprotein 1 (PSG1) secreted by placenta trophoblast cells is utilized to improve the abnormal development of the lost region and the connecting region of the placenta, which highlights the key effect of PSG1 in promoting placenta development. The application of the invention possibly exceeds heart diseases, and provides a new way for treating other fetal dysplasia caused by placental insufficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a PSG1 recombinant protein containing FLAG and His tags and an application thereof. Background Art

[0002] Scientific research shows that abnormal placental development is the main cause of fetal death and congenital heart disease. Congenital heart disease is one of the most common birth defects, with high morbidity and mortality, seriously affecting the quality of life of millions of newborns and their families. If heart development abnormalities are diagnosed during the fetal period, there is usually a lack of other effective treatments except surgical treatment. This situation shows the limitations in the field of treating embryonic congenital heart disease and the urgent need for more advanced treatments.

[0003] At present, the treatment of congenital heart disease mainly relies on physical intervention, such as surgery and catheter intervention, and there is a lack of specific drugs that can treat the disease in the embryonic period. Existing drug treatments are mainly aimed at improving the patient's heart function after birth and alleviating the disease process, but these drugs cannot act directly on the embryo and cannot correct the fetal heart development defects in the embryonic period. Although surgical treatment can significantly improve the survival rate of patients with congenital heart disease, this treatment option is usually accompanied by high risks and requires patients to undergo long-term medical monitoring. This not only affects the patient's quality of life, but also imposes a serious economic burden on patients and their families. Therefore, it is necessary to develop new therapies that can directly affect the development of the embryonic heart, aiming to provide patients with congenital heart disease with safer and more effective treatment options at an earlier stage to reduce the burden on patients and their families.

[0004] At present, there is a lack of a strategy for the treatment of congenital heart disease in my country that can be directly administered to the mother to effectively treat congenital heart disease in the early stages of fetal development. This gap indicates the need to develop new treatments that can provide more effective interventions during the critical period of embryonic development and correct fetal heart development abnormalities.

[0005] The occurrence of fetal congenital heart disease is often associated with abnormal placental development. Genetic studies based on mice have confirmed that placental defects can directly affect the normal development of the embryonic heart and are the main cause of congenital heart disease and embryonic death. These research results emphasize the key role of the placenta in embryonic heart morphogenesis and point out the important potential of considering placental targeted intervention in the treatment of congenital heart disease.

[0006] Pregnancy-specific glycoprotein 1 (PSG1) is an important substance secreted by placental trophoblast cells. Currently, there is a lack of a PSG1 recombinant protein containing both FLAG and His tags and its application. Summary of the invention

[0007] In order to overcome the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a PSG1 recombinant protein containing FLAG and His tags and applications thereof.

[0008] In order to achieve the above technical objectives, the technical solutions adopted by the present invention are as follows: In the first aspect, the present application provides a pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags; in the second aspect, the present invention provides an application of a PSG1 recombinant protein containing FLAG and His tags in the preparation of drugs for placental dysplasia and fetal birth defects; in the third aspect, the present invention provides a method for detecting the expression of PSG1 recombinant protein in the placenta; in the fourth aspect, the present invention provides a method for preparing a PSG1 recombinant protein containing FLAG and His tags; in the fifth aspect, the present invention provides a model for evaluating the effect of PSG1 recombinant protein on embryonic heart development.

[0009] In a first aspect, the present application provides a pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags, wherein the recombinant protein is constructed by adding FLAG and His tag sequences to the C-terminus of the PSG1 gene sequence; the nucleotide sequence of the PSG1 recombinant protein containing FLAG and His tags is shown in SEQ ID NO.1.

[0010] The concentration of the recombinant protein reaches 5.4 mg / ml and the purity is 95%. The recombinant protein is used to treat abnormalities in placental and embryonic heart development.

[0011] The second aspect of the present application provides a use of a pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags in the preparation of drugs for placental dysplasia and fetal birth defects. 100 μg of PSG1 recombinant protein is injected into pregnant mice on E8.5 and E10.5 days of embryonic development through maternal intravenous administration.

[0012] Furthermore, the development of the placenta and embryos was examined in detail at E11.5 to evaluate the therapeutic effect of PSG1 recombinant protein.

[0013] Furthermore, the recombinant protein can significantly promote the development of the placenta and embryo, improve the developmental abnormalities of the placental labyrinth and connection zones, and promote the development of the ventricular wall and improve the heart structure.

[0014] Furthermore, the recombinant protein has the biological activity of promoting the damaged placenta to restore normal development and improve the heart structure.

[0015] The third aspect of the present application provides a method for detecting the expression of PSG1 recombinant protein in the placenta, comprising the following steps: detecting the expression of PSG1 protein by immunofluorescence staining using an anti-FLAG antibody.

[0016] The fourth aspect of the present application provides a method for preparing a PSG1 recombinant protein containing FLAG and His tags, comprising the following steps: using a HEK-293 eukaryotic expression system to express and purify the protein, and storing the obtained recombinant protein in a buffer (pH 8.0) containing 20 mM HEPES and 300 mM NaCl.

[0017] In a fifth aspect, the present application provides a model for evaluating the effect of PSG1 recombinant protein on embryonic heart development, using a mouse model with Slc25a1 gene deletion, and observing changes in cardiac structure after PSG1 treatment.

[0018] Beneficial effects: The present invention utilizes pregnancy-specific glycoprotein 1 (PSG1) secreted by placental trophoblast cells to improve the developmental abnormalities of the placental labyrinth and junctional regions, which highlights the key role of PSG1 in promoting placental development. The application of the present invention may go beyond heart disease and provide a new treatment approach for other fetal developmental abnormalities caused by placental insufficiency.

[0019] Compared with the prior art, the present invention has the following advantages: (1) Improving the structure of the embryonic heart: PSG1 treatment significantly increases the overall size of the embryonic heart, promotes the development of the ventricular wall, and improves the structure of the heart, which has an important positive impact on the overall healthy development of the embryo.

[0020] (2) Potential for treating congenital heart disease: PSG1 treatment can effectively reverse cardiac dysplasia caused by Slc25a1 gene deletion, providing a potential therapeutic strategy for treating related heart diseases.

[0021] (3) The present invention aims to improve the success rate of treatment and reduce the incidence of congenital heart disease through early intervention.

[0022] (4) Safe and effective treatment options: The present invention provides a simple maternal intravenous administration method that can safely and effectively promote the healthy development of the placenta and fetal heart.

[0023] (5) Reducing the burden on patients and their families: By providing an earlier and more effective treatment method, the present invention helps to reduce the economic and psychological burden on patients with congenital heart disease and their families. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0025] Figure 1 The PSG1 recombinant protein of the present invention improves mouse placental development defects. Figure 1 A shows hematoxylin-eosin staining of three groups of mouse placentas: control group (Slc25a1+ / +), Slc25a1 knockout group (Slc25a1- / -), and PSG1 treatment group (Slc25a1- / -+PSG1). The dotted lines divide the three layers of the placenta, Dec: decidual zone; JZ: junction zone; Lab: labyrinth zone. The scale bar of the picture is 200μm. Figure 1 B The quantification results showed that the thickness of the placenta in the labyrinth and junctional zones of mice treated with PSG1 was significantly restored compared with the Slc25a1 knockout group.

[0026] Figure 2 The PSG1 recombinant protein of the present invention can improve the cardiac structure of Slc25a1 gene-deficient mice. Figure 2 A is a diagram of the heart of mice with different genotypes and after PSG1 treatment of the present invention: control group (Slc25a1+ / +), Slc25a1 gene knockout group (Slc25a1- / -) and PSG1 treatment group (Slc25a1- / -+PSG1). The white line in the figure outlines the ventricular part of the heart, and marks the right ventricle (RV) and left ventricle (LV). It can be observed from the image that the heart morphology of Slc25a1- / - mice is significantly different from that of the control group mice, indicating that the loss of the Slc25a1 gene affects the heart structure, resulting in abnormal development of the mouse embryonic heart and reduced ventricle; after PSG1 treatment, the heart morphology is partially restored. The scale of the picture is 200μm. Figure 2 B is a bar graph of the present invention showing the ventricular area of ​​the mouse heart. Compared with Slc25a1+ / + mice, the ventricular area of ​​Slc25a1- / - mice was significantly reduced, and after PSG1 treatment, the ventricular area of ​​Slc25a1- / - mice was significantly restored. Data are expressed as mean ± standard deviation, **P<0.01. These results confirm the effectiveness of PSG1 treatment in improving cardiac structure.

[0027] Figure 3 The PSG1 recombinant protein of the present invention can improve the ventricular wall development of Slc25a1 gene-deficient mice; Figure 3A is a fluorescent image of the heart sections of mice in the control group (Slc25a1+ / +), Slc25a1 knockout group (Slc25a1- / -) and PSG1 treatment group (Slc25a1- / -+PSG1) of the present invention. The left panel shows the overall structure of the mouse heart, and the right panel shows the numbered dotted box area in the left heart at a higher magnification. Figure 3 B is the quantitative data of the present invention showing the comparison of the thickness of the right ventricular wall and the left ventricular wall of the three groups of mice. The data are expressed as mean ± standard deviation, ***P<0.001, and these results confirm that PSG1 can effectively improve the development of the ventricular wall of mice.

[0028] Figure 4 It is a structural diagram of the PSG1 recombinant protein of the present invention.

[0029] Figure 5 The figure is a timeline diagram of drug administration and analysis during mouse embryonic development of the present invention.

[0030] Figure 6 This is an immunofluorescence staining image of the FLAG antibody of the mouse placenta of the present invention. DETAILED DESCRIPTION

[0031] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0032] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.

[0033] In this application, "at least one" means one or more, and "plurality" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b, or c", or "at least one of a, b, and c" can all mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.

[0034] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0035] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "said" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0036] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.

[0037] In a first aspect, an embodiment of the present application provides a pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags, wherein the recombinant protein is constructed by adding FLAG and His tag sequences to the C-terminus of the PSG1 gene sequence; the nucleotide sequence of the PSG1 recombinant protein containing FLAG and His tags is shown in SEQ ID NO.1.

[0038] The concentration of the recombinant protein reaches 5.4 mg / ml and the purity is 95%. The recombinant protein is used to treat abnormalities in placental and embryonic heart development.

[0039] A second aspect of an embodiment of the present application provides an application of a pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags in the preparation of drugs for placental dysplasia and fetal birth defects. 100 μg of PSG1 recombinant protein is injected into pregnant mice on E8.5 and E10.5 days of embryonic development through maternal intravenous administration.

[0040] In some embodiments, the development of the placenta and embryos is carefully examined at day E11.5 to assess the therapeutic effect of PSG1 recombinant protein.

[0041] In some embodiments, the recombinant protein can significantly promote the development of the placenta and embryo, improve the developmental abnormalities of the placental labyrinth and connection zones, and promote the development of the ventricular wall and improve the heart structure.

[0042] In some embodiments, the recombinant protein has biological activity of promoting the recovery of damaged placenta to normal development and improving heart structure.

[0043] A third aspect of an embodiment of the present application provides a method for detecting the expression of PSG1 recombinant protein in the placenta, comprising the following steps: detecting the expression of PSG1 protein by immunofluorescence staining using an anti-FLAG antibody.

[0044] The fourth aspect of the embodiment of the present application provides a method for preparing a PSG1 recombinant protein containing FLAG and His tags, comprising the following steps: using a HEK-293 eukaryotic expression system to express and purify the protein, and storing the obtained recombinant protein in a buffer (pH 8.0) containing 20 mM HEPES and 300 mM NaCl.

[0045] A fifth aspect of the embodiments of the present application provides a model for evaluating the effect of PSG1 recombinant protein on embryonic heart development, using a mouse model with Slc25a1 gene deletion to observe changes in cardiac structure after PSG1 treatment.

[0046] Example 1

[0047] In the labyrinth of the placenta, there are abundant fetal blood vessels and maternal blood cavity, as well as various types of trophoblast cells, such as syncytial trophoblast cells, sinusoidal trophoblast giant cells, etc., which are responsible for nutrient transport and gas exchange between the mother and the fetus. The connection area of ​​the placenta is mainly composed of spongy trophoblast cells, glycogen trophoblast cells and different types of giant cells, which constitute the main endocrine compartment of the placenta. During pregnancy, the placenta secretes a variety of hormones and growth factors, which not only promote the normal development of the fetus and placenta, but also enter the maternal blood to help the mother adapt to the physiological changes during pregnancy, thereby supporting the continued growth and development of the fetus.

[0048] The present invention uses a mouse model with Slc25a1 gene deletion to explore the effect of PSG1 on placental and embryonic development. In this study, the present invention found that the development of the labyrinth and junctional regions of the placenta of Slc25a1 gene-deficient mice was impaired, and their thickness was significantly lower than that of the normal control group. However, after treatment with PSG1 recombinant protein, the thickness of the labyrinth and junctional regions of these placentas was significantly restored ( Figure 1 ). These results suggest that PSG1 has a potential role in promoting normal placental development.

[0049] Figure 1 The PSG1 recombinant protein of the present invention improves mouse placental development defects.

[0050] Figure 1A is a hematoxylin-eosin staining image of three groups of mouse placentas of the present invention: control group (Slc25a1+ / +), Slc25a1 gene knockout group (Slc25a1- / -) and PSG1 treatment group (Slc25a1- / -+PSG1). The dotted lines divide the three-layer structure of the placenta, Dec: decidual zone; JZ: junction zone; Lab: labyrinth zone. The scale of the picture is 200 μm. Figure 1 B The quantitative results show that the thickness of the placenta in the labyrinth and junctional areas of mice treated with PSG1 was significantly restored compared with the Slc25a1 knockout group. This result further confirms the potential role of PSG1 in promoting the recovery of normal development of damaged placentas and provides an important scientific basis for the treatment of related placental developmental abnormalities. Data are expressed as mean ± standard deviation. **P<0.01, ***P<0.001.

[0051] Placental defects are an important factor leading to congenital heart disease, and in the mouse model of Slc25a1 gene deficiency, a significant reduction in cardiac structure was observed. However, after treatment with PSG1, the ventricular structure of these mice was restored ( Figure 2 This finding suggests that PSG1 treatment can effectively reverse the cardiac dysplasia caused by Slc25a1 gene deletion, providing a potential therapeutic strategy for the treatment of related heart diseases.

[0052] Figure 2 The PSG1 recombinant protein of the present invention can improve the cardiac structure of Slc25a1 gene-deficient mice. Figure 2 A is a diagram of the heart of mice of different genotypes and after PSG1 treatment of the present invention: control group (Slc25a1+ / +), Slc25a1 gene knockout group (Slc25a1- / -) and PSG1 treatment group (Slc25a1- / -+PSG1). The white line in the figure outlines the ventricular part of the heart, marking the right ventricle (RV) and left ventricle (LV). It can be observed from the image that the heart morphology of Slc25a1- / - mice is significantly different from that of the control group mice, indicating that the loss of the Slc25a1 gene affects the heart structure, resulting in abnormal development of the mouse embryonic heart and reduced ventricle; and after PSG1 treatment, the heart morphology is partially restored. The scale of the picture is 200μm. Figure 2 B is a bar graph of the present invention that quantifies the ventricular area of ​​the mouse heart. Compared with the control mice, the ventricular area of ​​the Slc25a1- / - mice was significantly reduced, while the ventricular area of ​​the Slc25a1- / - mice treated with PSG1 was significantly improved, approaching the heart size of normal mice. Data are expressed as mean ± standard deviation, **P<0.01. These results confirm the effectiveness of PSG1 treatment in improving cardiac structure.

[0053] At E11.5 days, ventricular wall thickness is a key indicator for assessing cardiac structure and function. Moderate thickening of the ventricular wall is an important component of normal cardiac morphogenesis and is essential for ensuring the heart's effective pumping function. Therefore, the measurement of ventricular wall thickness can be used as an important indicator for assessing the health of embryonic heart development. The present invention further observed the structure of the mouse ventricular wall by immunofluorescence staining. In mice with a missing Slc25a1 gene, the ventricular wall was significantly thinner than that of the control group. However, after treatment with PSG1, the ventricular wall thickness of these mice was significantly improved ( Figure 3 This result indicates that PSG1 has a potential role in promoting heart development and provides an important experimental basis for possible future therapeutic strategies.

[0054] Figure 3 The PSG1 recombinant protein of the present invention can improve the ventricular wall development of Slc25a1 gene-deficient mice. Figure 3 A is a fluorescent image of the heart sections of mice in the control group (Slc25a1+ / +), Slc25a1 knockout group (Slc25a1- / -) and PSG1 treatment group (Slc25a1- / -+PSG1) of the present invention. The left panel shows the overall structure of the mouse heart, and the right panel shows the numbered dotted box area in the left heart at a higher magnification. In these high-magnification images, white segments are used to indicate the thickness of the ventricular wall. Heart sections were stained with DAPI, cTnT and Endomucin, respectively, where DAPI marked the nucleus in blue; cTnT specifically marked the cardiomyocytes in red; and Endomucin marked the endocardial cells in green. The experimental results highlight the effects of Slc25a1 gene deletion and PSG1 treatment on the structure of the ventricular wall of the heart. In mice with Slc25a1 gene deletion, the ventricular wall became thinner; but after PSG1 treatment, the thickness of the ventricular wall was significantly improved, similar to that of wild-type mice. The image scale is 100μm. Figure 3 Part B shows the comparison of the thickness of the right and left ventricular walls of the three groups of mice through quantitative data. The data are expressed as mean ± standard deviation, ***P<0.001. These results confirm that PSG1 can effectively improve the development of the ventricular wall of mice.

[0055] Example 2

[0056] Construction of PSG1 recombinant protein

[0057] The present invention first retrieved the sequence of the PSG1 gene from the National Center for Biotechnology Information (NCBI). Subsequently, the HEK-293 cell eukaryotic expression system was used to construct a PSG1 recombinant protein containing FLAG and His tags. The specific sequence of the obtained recombinant protein has been described in detail in the application document. The concentration of the recombinant protein reached 5.4 mg / ml, the purity was 95%, and it was stored in a buffer (pH 8.0) containing 20 mM HEPES and 300 mM NaCl.

[0058] In the experiment, the present invention mated mice at regular intervals, and the day of successful mating was regarded as embryonic day 0.5 (E0.5). At E8.5 and E10.5 of embryonic development, 100 μg of PSG1 recombinant protein was injected into pregnant mice through the tail vein. At E11.5, the development of the placenta and embryo was examined in detail.

[0059] First, the complete sequence of the PSG1 gene was obtained by querying the public database, and FLAG and His tags were added to its C-terminus for subsequent detection and purification ( Figure 4 ). The protein was expressed and purified using the HEK-293 eukaryotic expression system.

[0060] The gene sequence of the PSG1 recombinant protein of the present invention comprises a FLAG tag sequence and a 6X His sequence. Figure 4 The structure diagram of the PSG1 recombinant protein of the present invention is shown in SEQ ID NO. 1. The nucleotide sequence of the PSG1 recombinant protein containing FLAG and His tags is shown in SEQ ID NO. 2.

[0061]

[0062]

[0063] Test Example 1

[0064] Timeline of drug administration and analysis during mouse embryonic development

[0065] Embryogenesis is a very complex biological process regulated by multiple factors. It originates from the fertilized egg formed by the combination of oocyte and sperm. When the embryo develops to E8.5 days, the fetal neural tube starts the closure program. As the precursor structure for the future development of the brain and spinal cord, the complete closure of the neural tube is crucial for the development of the fetal nervous system. Incomplete closure of the neural tube may lead to serious and potentially fatal congenital malformations. At E8.5 days, the allantois contacts and fuses with the chorion, spreads on the surface of the chorionic plate, and promotes the development of the placental labyrinth. The allantois is the precursor tissue of the mature umbilical cord, connecting the fetus and the mother through blood vessels. Therefore, E8.5 days is a critical time node for the development of both the embryo and the placenta. At E10.5 days, the neural tube is closed, and the structure of the placental labyrinth becomes more complex, which can effectively carry out gas exchange, nutrient delivery, and metabolic waste discharge, thereby supporting the continued development and maturation of the embryo. Therefore, the present invention selects the key period of embryonic and placental development, that is, E8.5 days and E10.5 days, to inject PSG1 into the tail vein of pregnant mice, and evaluates the potential improvement effect of PSG1 on embryonic and placental development on E11.5 days ( Figure 5 ). Figure 5 The figure is a timeline diagram of drug administration and analysis during mouse embryonic development of the present invention.

[0066] This timeline diagram details the key time points from mouse fertilization to analysis of embryonic and placental development. E0.5 stands for day 0.5 after fertilization, marking the beginning of mouse embryonic development. E8.5 and E10.5 are the time points for injection of PSG1 recombinant protein or saline via the maternal tail vein. E11.5 is the time point for analysis of embryonic and placental development, marked with a scissors icon.

[0067] Test Example 2

[0068] Treatment efficiency test of PSG1 recombinant protein

[0069] The present invention treats pregnant mice with tail vein injections at E8.5 days and E10.5 days, respectively injecting physiological saline and 100 μg of PSG1 recombinant protein. This method aims to evaluate the effects of PSG1 on embryonic development and placental function, and compares the results with those of the control group to determine the potential therapeutic effect of PSG1. At E11.5 days, placental samples are taken from these pregnant mice, sliced, and immunofluorescence staining is performed using anti-FLAG antibodies to detect the expression of PSG1 protein, thereby evaluating the efficiency of drug administration. In the placenta of mice treated with PSG1, clear expression of the FLAG tag was observed by immunofluorescence staining. This result not only proves the successful expression of PSG1 protein in the placenta, but also directly reflects the high efficiency of drug administration. This discovery provides strong evidence for the biological activity of PSG1 recombinant protein and its potential for in vivo application, and supports its further development and utilization in medical research and therapeutic applications.

[0070] Figure 6 This is an immunofluorescence staining image of the FLAG antibody of the mouse placenta of the present invention.

[0071] Immunofluorescence staining analysis was performed on the placenta of pregnant mouse embryos injected with PSG1 and saline via the tail vein. Through this method, the present invention can observe and compare the expression of PSG1 recombinant protein in the placenta of the treatment group and the saline control group. The scale of the picture is 200 μm.

[0072] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and the scope of protection of the present invention is defined by the attached claims, description and their equivalents.

Claims

1. A pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags, characterized in that: The recombinant protein is constructed by adding FLAG and His tag sequences to the C-terminus of the PSG1 gene sequence; the nucleotide sequence of the PSG1 recombinant protein containing FLAG and His tags is shown in SEQ ID NO.

1.

2. Use of the pregnancy-specific glycoprotein 1 (PSG1) recombinant protein containing FLAG and His tags according to claim 1 in the preparation of drugs for placental dysplasia and fetal birth defects, characterized in that: Pregnant mice were injected with 100 μg of PSG1 recombinant protein via maternal intravenous administration on embryonic days E8.5 and E10.

5.

3. The use according to claim 2, characterized in that: The development of the placenta and embryos was examined in detail at E11.5 to evaluate the therapeutic effect of PSG1 recombinant protein.

4. The use according to claim 3, characterized in that: The recombinant protein can significantly promote the development of the placenta and embryo, improve the developmental abnormalities of the placental labyrinth and connection areas, and promote the development of the ventricular wall and improve the heart structure.

5. The use according to claim 4, characterized in that: The recombinant protein has the biological activity of promoting the damaged placenta to recover normal development and improving the heart structure.

6. A method for detecting the expression of PSG1 recombinant protein in placenta, characterized in that The method comprises the following steps: detecting the expression of PSG1 protein by immunofluorescence staining using anti-FLAG antibody.

7. A method for preparing a PSG1 recombinant protein containing FLAG and His tags, characterized in that The method comprises the following steps: using a HEK-293 eukaryotic expression system to express and purify a protein, and storing the obtained recombinant protein in a buffer (pH 8.0) containing 20 mM HEPES and 300 mM NaCl.

8. A model for evaluating the effect of PSG1 recombinant protein on embryonic heart development, characterized in that: Using a mouse model with Slc25a1 gene deletion, changes in cardiac structure were observed after PSG1 treatment.

Citation Information

Patent Citations

  • Establishment of Kinase protein Akt1 conditional gene knockout mice model and application

    CN102477421A

  • Prokaryotic expression strain of TREM-1 extracellular domain, and application of prokaryotic expression strain in treating septicemia caused by streptococcus suis infection.

    CN103409359A

  • Pregnancy-specific glycoprotein 3 standard substance, preparation method thereof and recombinant strain used for preparation

    CN105505943A

  • Treatment of cerebrovascular events and nervous system diseases

    CN117651564A

  • Protein for promoting nerve differentiation and resisting cell death, and its coding gene

    CN1544465A